![Perry Nisen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Perry Nisen
Direktor/Vorstandsmitglied bei
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Vermögen: 4 Mio $ am 31.05.2026
Profil
Perry D.
Nisen is Chief Executive Officer & Director at Quanta Therapeutics, Inc. since 2021.
Dr. Nisen is Independent Director at Teva Pharmaceutical Industries Ltd. since 2017.
Dr. Nisen is Director at California Biomedical Innovation Alliance since 2015.
Former roles include Chief Executive Officer & Trustee at Sanford Burnham Prebys Medical Discovery Institute from 2014 to 2017, Independent Director at Mirna Therapeutics, Inc. from 2016 to 2017, Director at Xylocor Therapeutics, Inc., Vice President-Cancer Research & Oncology Development at Abbott Laboratories from 1997 to 2004, Professor at The University of Texas Southwestern Medical Center, Senior Vice President-Science & Innovation at GlaxoSmithKline LLC from 2004 to 2014, and Executive Partner & Private Equity at Sofinnova Investments, Inc. Education includes undergraduate degree from Stanford University in 1977, and graduate and doctorate degrees from Albert Einstein College of Medicine, Inc. in 1979 and 1982 respectively.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 05.06.2026 | 119.807 ( 0,01 % ) | 4 Mio $ | 31.05.2026 |
Aktive Positionen von Perry Nisen
| Unternehmen | Position | Beginn |
|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Direktor/Vorstandsmitglied | 14.07.2017 |
California Biomedical Innovation Alliance
 California Biomedical Innovation Alliance BiotechnologyHealth Technology Provides biomedical advocacy and community services | Direktor/Vorstandsmitglied | 23.11.2015 |
Quanta Therapeutics, Inc.
 Quanta Therapeutics, Inc. BiotechnologyHealth Technology Develops biotechnologies | Vorstandsvorsitzender | 01.07.2021 |
Ehemalige bekannte Positionen von Perry Nisen
| Unternehmen | Position | Ende |
|---|---|---|
Sanford Burnham Prebys Medical Discovery Institute
 Sanford Burnham Prebys Medical Discovery Institute Medical/Nursing ServicesHealth Services Conducts medical research | Vorstandsvorsitzender | 30.09.2017 |
Mirna Therapeutics, Inc.
 Mirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in the development of micro ribonucleic acid based oncology therapeutics | Direktor/Vorstandsmitglied | 01.01.2017 |
GlaxoSmithKline LLC
 GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Corporate Officer/Principal | 01.09.2014 |
| ABBOTT LABORATORIES | Corporate Officer/Principal | 01.01.2004 |
Xylocor Therapeutics, Inc.
 Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops novel gene therapy for cardiovascular disease | Direktor/Vorstandsmitglied | - |
Ausbildung von Perry Nisen
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
99
Beziehungen ersten Grades
12
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 12 |
|---|---|
Abbott Laboratories
 Abbott Laboratories Medical SpecialtiesHealth Technology Develops and manufactures medical devices, diagnostic systems, pharmaceuticals & nutritional products | Health Technology |
Teva Pharmaceutical Industries Ltd.
 Teva Pharmaceutical Industries Ltd. Pharmaceuticals: GenericHealth Technology Manufactures and markets generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients | Health Technology |
Sofinnova Investments, Inc.
 Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment invests in companies located in the United States and Europe. The firm targets companies operating in the fields of health technology services and life science. It participates in early and later stage capital requirements. | Finance |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sanford Burnham Prebys Medical Discovery Institute
Sanford Burnham Prebys Medical Discovery Institute Medical/Nursing ServicesHealth Services Conducts medical research | Health Services |
Mirna Therapeutics, Inc.
Mirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in the development of micro ribonucleic acid based oncology therapeutics | Commercial Services |
Albert Einstein College of Medicine, Inc.
 Albert Einstein College of Medicine, Inc. Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Texas Southwestern Medical Center
 The University of Texas Southwestern Medical Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Health Technology |
California Biomedical Innovation Alliance
California Biomedical Innovation Alliance BiotechnologyHealth Technology Provides biomedical advocacy and community services | Health Technology |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops novel gene therapy for cardiovascular disease | Health Technology |
Quanta Therapeutics, Inc.
Quanta Therapeutics, Inc. BiotechnologyHealth Technology Develops biotechnologies | Health Technology |
